Volume | 679,346 |
|
|||||
News | - | ||||||
Day High | 1.51 | Low High |
|||||
Day Low | 1.45 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
AVROBIO Inc | AVRO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.46 | 1.45 | 1.51 | 1.51 | 1.41 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,178 | 679,346 | $ 1.48 | $ 1,005,560 | - | 0.8801 - 1.65 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:02:45 | 1 | $ 1.52 | USD |
AVROBIO Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
67.74M | 44.86M | - | 0 | 12.4M | 0.28 | 5.46 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
AVROBIO News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AVRO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.38 | 1.51 | 1.33 | 1.40 | 235,755 | 0.13 | 9.42% |
1 Month | 1.18 | 1.51 | 1.1705 | 1.30 | 302,559 | 0.33 | 27.97% |
3 Months | 1.29 | 1.51 | 1.15 | 1.28 | 209,195 | 0.22 | 17.05% |
6 Months | 1.24 | 1.52 | 1.01 | 1.28 | 250,486 | 0.27 | 21.77% |
1 Year | 1.288 | 1.65 | 0.8801 | 1.34 | 560,119 | 0.222 | 17.24% |
3 Years | 9.19 | 11.17 | 0.56 | 1.92 | 684,598 | -7.68 | -83.57% |
5 Years | 15.90 | 29.32 | 0.56 | 5.44 | 544,983 | -14.39 | -90.50% |
AVROBIO Description
Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3; and AVR-RD-03 for the treatment of Pompe disease. |